Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George Ehrlich

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Journal of Molecular Recognition : JMR|February 6, 2009
Affinity 2007Gideon Fleminger, George Ehrlich
Current Rheumatology Reports|January 19, 2002
Behçet's disease: immunopathologic and therapeutic aspectsRobert Meador, George Ehrlich, Joan M Von Feldt
Nature Communications|November 12, 2024
Structures of complete extracellular assemblies of type I and type II Oncostatin M receptor complexesYi Zhou, Panayiotis E Stevis, Jing Cao, et al.
Bioanalysis|March 17, 2022
Assay pH and critical reagent optimization in measuring concentrations of a monoclonal antibody and its targetJihua Chen, Kimberly Kendra, Stacey Shank, et al.
Molecular Pharmaceutics|April 24, 2018
ImmunoPET Imaging of Endogenous and Transfected Prolactin Receptor Tumor XenograftsSarah M Cheal, Shutian Ruan, Darren R Veach, et al.
Plos One|May 9, 2020
Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5Adrianna Latuszek, Yashu Liu, Olav Olsen, et al.
Scientific Reports|August 21, 2019
A novel bispecific antibody platform to direct complement activity for efficient lysis of target cellsJonathan W Cruz, Ermelinda Damko, Bhavika Modi, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 28, 2019
Kappa-on-Heavy (KoH) bodies are a distinct class of fully-human antibody-like therapeutic agents with antigen-binding propertiesLynn E Macdonald, Karoline A Meagher, Matthew C Franklin, et al.
Science Translational Medicine|November 6, 2024
Monoclonal antibodies against the spike protein alter the endogenous humoral response to SARS-CoV-2 vaccination and infectionChristopher D Petro, Andrea T Hooper, Avery Peace, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Journal of Molecular Recognition : JMR|February 6, 2009
Affinity 2007Gideon Fleminger, George Ehrlich
Current Rheumatology Reports|January 19, 2002
Behçet's disease: immunopathologic and therapeutic aspectsRobert Meador, George Ehrlich, Joan M Von Feldt
Nature Communications|November 12, 2024
Structures of complete extracellular assemblies of type I and type II Oncostatin M receptor complexesYi Zhou, Panayiotis E Stevis, Jing Cao, et al.
Bioanalysis|March 17, 2022
Assay pH and critical reagent optimization in measuring concentrations of a monoclonal antibody and its targetJihua Chen, Kimberly Kendra, Stacey Shank, et al.
Molecular Pharmaceutics|April 24, 2018
ImmunoPET Imaging of Endogenous and Transfected Prolactin Receptor Tumor XenograftsSarah M Cheal, Shutian Ruan, Darren R Veach, et al.
Plos One|May 9, 2020
Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5Adrianna Latuszek, Yashu Liu, Olav Olsen, et al.
Scientific Reports|August 21, 2019
A novel bispecific antibody platform to direct complement activity for efficient lysis of target cellsJonathan W Cruz, Ermelinda Damko, Bhavika Modi, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 28, 2019
Kappa-on-Heavy (KoH) bodies are a distinct class of fully-human antibody-like therapeutic agents with antigen-binding propertiesLynn E Macdonald, Karoline A Meagher, Matthew C Franklin, et al.
Science Translational Medicine|November 6, 2024
Monoclonal antibodies against the spike protein alter the endogenous humoral response to SARS-CoV-2 vaccination and infectionChristopher D Petro, Andrea T Hooper, Avery Peace, et al.
Pageof 1